Nob Hill Therapeutics, Inc. (NHT) is developing new technologies and therapies for lung-related diseases that can’t be effectively treated today. These diseases impact millions of patients, and the annual market potential for many of these diseases is substantial (e.g., lung cancer – $30b, Cystic Fibrosis – $13b, Invasive fungal infections – $9b). Nob Hill has developed a novel drug inhalation device platform that solves many disadvantages with today’s technologies. NHT also is working on developing accompanying drug-device combination products that will serve as PoC for the technology (with addressable US markets of $1.75b annual sales).
Drug Inhalation Technology Advantage: Traditional dry powder inhaler products (e.g., Advair Diskus, Tobi PodHaler) have two main disadvantages: (1) they cannot deliver the high doses of medicine required to treat many respiratory diseases and (2) they require patients to strongly inhale through the device to deliver sufficient drug to the lungs, which is ineffective as many patients with lung conditions have compromised breathing capability.
NHT’s DryNeb inhalation platform overcomes these disadvantages:
Product Pipeline: The DryNeb platform can be used with almost any dry powder active pharmaceutical ingredient (API). NHT’s current pipeline is focused on approved drugs that have treatment advantages when paired with pulmonary delivery. NHT’s lead product (NHT102) is an inhaled small molecule for lung cancer and is supported by an SBIR grant ($2m). The efficacy of this inhaled molecule has been demonstrated in PoC animal and human studies. NHT’s second product (NHT101) is an inhaled antifungal directed at treating Aspergillosis and is supported by SBIR grants ($2m). NHT has completed an animal efficacy study with compelling results.
Market Opportunity:
Investment information is restricted to VIN members. Become a member to view investment opportunities.